Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses

Antiviral Res. 2014 May:105:54-8. doi: 10.1016/j.antiviral.2014.02.017. Epub 2014 Feb 28.

Abstract

The efficacy of oseltamivir-zanamivir combination therapy compared to that of monotherapy was evaluated in mice infected with influenza A(H3N2) or A(H1N1)pdm09 viruses. For A(H3N2) virus, zanamivir monotherapy and oseltamivir-zanamivir combination showed significant reduction of mean weight loss compared to oseltamivir. Zanamivir monotherapy also conferred decreased mortality, weight loss and lung viral titers (LVT) compared to oseltamivir for A(H1N1)pdm09 wild-type virus. Intermediate benefits were observed for the oseltamivir-zanamivir combination. For the oseltamivir-resistant A(H1N1)pdm09 H275Y virus, the efficacy of oseltamivir-zanamivir was comparable to that of zanamivir and significantly higher than that of oseltamivir in terms of survival, weight loss and LVT.

Keywords: Combination; Influenza; Neuraminidase inhibitors; Oseltamivir; Resistance; Zanamivir.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use*
  • Body Weight
  • Disease Models, Animal
  • Drug Therapy, Combination / methods
  • Influenza A Virus, H1N1 Subtype / isolation & purification*
  • Influenza A Virus, H3N2 Subtype / isolation & purification*
  • Lung / virology
  • Mice, Inbred C57BL
  • Orthomyxoviridae Infections / drug therapy*
  • Orthomyxoviridae Infections / virology
  • Oseltamivir / therapeutic use*
  • Survival Analysis
  • Treatment Outcome
  • Viral Load
  • Zanamivir / therapeutic use*

Substances

  • Antiviral Agents
  • Oseltamivir
  • Zanamivir